Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease

Though Abl inhibitors are often successful therapies for the initial stages of chronic myelogenous leukemia (CML), refractory cases highlight the need for novel molecular insights. We demonstrate that mice deficient in the enzyme 12/15-lipoxygenase (12/15-LO) develop a myeloproliferative disorder (M...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Middleton, Melissa Kristine, Zukas, Alicia Marie, Rubinstein, Tanya, Jacob, Michele, Zhu, Peijuan, Zhao, Liang, Blair, Ian, Puré, Ellen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Rockefeller University Press 2006
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2118138/
https://ncbi.nlm.nih.gov/pubmed/17043146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20061444
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak